Babaluke的个人主页 - 老虎社区

Babaluke

Babaluke

暂无个人介绍

IP属地：未知

0关注

0粉丝

0主题

0勋章

2021-06-23

Great ariticle, would you like to share it?

@小虎活动:【老虎7周年】集卡瓜分百万奖金

2021-06-23

Ok

抱歉，原内容已删除

2021-06-23

Ok

EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote>

2021-06-23

What

EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote>

2021-06-23

Yums

Krispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转移到线上，Krispy Kreme 寻求 6.4 亿美元 IPO</blockquote>

2021-06-23

Ok

抱歉，原内容已删除

2021-06-23

Cool

抱歉，原内容已删除

2021-06-23

Good

抱歉，原内容已删除

2021-06-23

Good

FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管有一些工作人员的担忧，FDA 还是批准了百健阿尔茨海默病药物</blockquote>

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3584774162933077","uuid":"3584774162933077","gmtCreate":1621680138843,"gmtModify":1624441399370,"name":"Babaluke","pinyin":"babaluke","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":0,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":3,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":1,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":123566429,"gmtCreate":1624429967061,"gmtModify":1634006224487,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123566429","repostId":"114899451","repostType":1,"repost":{"id":114899451,"gmtCreate":1623063308869,"gmtModify":1631884627596,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"36984908995200","idStr":"36984908995200"},"themes":[],"title":"【老虎7周年】集卡瓜分百万奖金","htmlText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> &#x1;如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。&#x1;如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 &#x1; &#x1;如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。&#x1; 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP &gt; 我的 &gt; 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","listText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> &#x1;如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。&#x1;如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 &#x1; &#x1;如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。&#x1; 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP &gt; 我的 &gt; 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","text":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ 戳我即可参与活动 \u0001如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。\u0001如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 \u0001 \u0001如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。\u0001 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP > 我的 > 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","images":[{"img":"https://static.tigerbbs.com/ab28db31a19b458d604a8bf02becddd3","width":"415","height":"125"},{"img":"https://static.tigerbbs.com/5227ebb594fe55b532c840acef147d7b","width":"415","height":"495"},{"img":"https://static.tigerbbs.com/92e88357b534f504b3088bc22f577a83","width":"415","height":"326"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114899451","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":8,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123518556,"gmtCreate":1624429005975,"gmtModify":1634006232788,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123518556","repostId":"2145671770","repostType":2,"isVote":1,"tweetType":1,"viewCount":3903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123510136,"gmtCreate":1624428873625,"gmtModify":1634006234187,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123510136","repostId":"1123710128","repostType":4,"repost":{"id":"1123710128","kind":"news","pubTimestamp":1624406277,"share":"https://www.laohunote.com/m/news/1123710128?lang=zh_CN&edition=full","pubTime":"2021-06-23 07:57","market":"us","language":"en","title":"EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123710128","media":"Bloomberg","summary":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than prev","content":"<p><div> (Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission ...</p><p><blockquote><div>（彭博社）——随着更严格的法规和日益增长的兴趣推动了对零排放的需求，全球电动汽车的霸主地位将于2033年到来，比之前预期提前了五年……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页连接</a></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 07:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> (Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission ...</p><p><blockquote><div>（彭博社）——随着更严格的法规和日益增长的兴趣推动了对零排放的需求，全球电动汽车的霸主地位将于2033年到来，比之前预期提前了五年……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123710128","content_text":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.\nConsultant Ernst & Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.\nStrict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.\nThe U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.\n“The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”\nThere also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.\n‘More Appealing’\n“Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”\nThe EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.\n“The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.\nAdditionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.\nEurope is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.\nVehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.","news_type":1,"symbols_score_info":{"TSLA":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":3618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597682,"gmtCreate":1624428375546,"gmtModify":1634006238087,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"title":"","htmlText":"What","listText":"What","text":"What","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597682","repostId":"1123710128","repostType":4,"repost":{"id":"1123710128","kind":"news","pubTimestamp":1624406277,"share":"https://www.laohunote.com/m/news/1123710128?lang=zh_CN&edition=full","pubTime":"2021-06-23 07:57","market":"us","language":"en","title":"EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123710128","media":"Bloomberg","summary":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than prev","content":"<p><div> (Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission ...</p><p><blockquote><div>（彭博社）——随着更严格的法规和日益增长的兴趣推动了对零排放的需求，全球电动汽车的霸主地位将于2033年到来，比之前预期提前了五年……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页连接</a></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 07:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> (Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission ...</p><p><blockquote><div>（彭博社）——随着更严格的法规和日益增长的兴趣推动了对零排放的需求，全球电动汽车的霸主地位将于2033年到来，比之前预期提前了五年……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123710128","content_text":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.\nConsultant Ernst & Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.\nStrict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.\nThe U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.\n“The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”\nThere also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.\n‘More Appealing’\n“Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”\nThe EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.\n“The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.\nAdditionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.\nEurope is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.\nVehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.","news_type":1,"symbols_score_info":{"TSLA":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":1826,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597355,"gmtCreate":1624428362077,"gmtModify":1634006238208,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Yums","listText":"Yums","text":"Yums","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597355","repostId":"1126010678","repostType":4,"repost":{"id":"1126010678","kind":"news","pubTimestamp":1624412603,"share":"https://www.laohunote.com/m/news/1126010678?lang=zh_CN&edition=full","pubTime":"2021-06-23 09:43","market":"us","language":"en","title":"Krispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转移到线上，Krispy Kreme 寻求 6.4 亿美元 IPO</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1126010678","media":"Bloomberg","summary":"(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise a","content":"<p><div> (Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering. The company said in a filing Tuesday that it ...</p><p><blockquote><div>（彭博社）——JAB Holdings BV 旗下的甜甜圈连锁店 Krispy Kreme Inc. 正寻求在首次公开募股中筹集高达 6.4 亿美元的资金。该公司在周二的一份文件中表示……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">网页连接</a></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Krispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转移到线上，Krispy Kreme 寻求 6.4 亿美元 IPO</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKrispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转移到线上，Krispy Kreme 寻求 6.4 亿美元 IPO</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 09:43</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> (Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering. The company said in a filing Tuesday that it ...</p><p><blockquote><div>（彭博社）——JAB Holdings BV 旗下的甜甜圈连锁店 Krispy Kreme Inc. 正寻求在首次公开募股中筹集高达 6.4 亿美元的资金。该公司在周二的一份文件中表示……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DNUT":"Krispy Kreme, Inc."},"source_url":"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126010678","content_text":"(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.\nThe company said in a filing Tuesday that it plans to sell almost 27 million shares for $21 to $24 apiece. At the top end of the range, Krispy Kreme would have a market value of $3.86 billion based on the outstanding shares listed in the filing with the U.S. Securities and Exchange Commission.\nAmid photos of doughnuts dripping with sugary glaze and dotted with sprinkles, the company declares in the filing that its purpose is “to touch and enhance lives through the joy of Krispy Kreme.”\nSince its acquisition by Luxembourg-based conglomerate JAB in 2016, Krispy Kreme has expanded its online presence. Its e-commerce business now accounts for close to a fifth of sales in the U.S., fueled by its Insomnia Cookies delivery concept.\nNet revenue for the Charlotte, North Carolina-based chain rose 23% to $322 million in the quarter ended April 4, according to the filing. Its net loss for the quarter shrunk from $11 million in 2020 to $378,000 this year.\nKrispy Kreme plans to use proceeds from the IPO to pay down debt and buy back shares from certain executives, as well as for general corporate purposes, according to the filing. JAB will continue to own almost 78% of the company’s shares after the IPO.\nThe offering is being led by JPMorgan Chase & Co., Morgan Stanley, Bank of America Corp. and Citigroup Inc. The company plans to list on the Nasdaq Global Select Market under the symbol DNUT.","news_type":1,"symbols_score_info":{"DNUT":0.9}},"isVote":1,"tweetType":1,"viewCount":3855,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123594843,"gmtCreate":1624428337982,"gmtModify":1634006238572,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123594843","repostId":"2145057786","repostType":4,"isVote":1,"tweetType":1,"viewCount":3903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123595713,"gmtCreate":1624428311132,"gmtModify":1634006238814,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123595713","repostId":"2145066250","repostType":4,"isVote":1,"tweetType":1,"viewCount":3363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592750,"gmtCreate":1624428287070,"gmtModify":1634006239664,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592750","repostId":"1192380860","repostType":4,"isVote":1,"tweetType":1,"viewCount":2233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592828,"gmtCreate":1624428233064,"gmtModify":1634006240151,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584774162933077","idStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592828","repostId":"1174011543","repostType":4,"repost":{"id":"1174011543","kind":"news","pubTimestamp":1624425845,"share":"https://www.laohunote.com/m/news/1174011543?lang=zh_CN&edition=full","pubTime":"2021-06-23 13:24","market":"us","language":"en","title":"FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管有一些工作人员的担忧，FDA 还是批准了百健阿尔茨海默病药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174011543","media":"WSJ","summary":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the obje","content":"<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p><p><blockquote>美国根据新公布的内部备忘录，美国食品和药物管理局批准了几十年来首个阿尔茨海默氏症新药，但该机构的统计人员表示反对，称没有足够的证据支持批准。</blockquote></p><p> In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p><p><blockquote>在周二发布的内部备忘录中，FDA 官员讨论了是否批准 fromBiogenInc.BIIB-1.71% 的药物，因为该机构药物统计办公室表示，临床试验数据达不到将新产品推向市场通常所需的证据。</blockquote></p><p> Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p><p><blockquote>根据备忘录，最终，高级官员决定，表明该药物有效的证据虽然不确定，但足以让医生和患者自行决定是否服用该药物。</blockquote></p><p> “FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p><p><blockquote>“美国食品和药物管理局新药办公室主任彼得-斯坦（Peter Stein）在一份备忘录中详细说明了他对批准 aducanumab 的支持，他写道：”美国食品和药物管理局新药办公室主任彼得-斯坦（Peter Stein）在一份备忘录中写道。“与此同时，[阿尔茨海默氏症]患者患有严重的、进行性的、最终致命的疾病，他们迫切需要治疗”。</blockquote></p><p> The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p><p><blockquote>FDA 公开了其内部审议，因为它面临一些医生和科学家对 6 月 7 日批准名为 Aduhelm 的药物的批评。</blockquote></p><p> The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p><p><blockquote>批评者称，FDA忽视了制药商通常遵守的科学标准，并可能促使联邦政府在一种可能无效的药物上花费数十亿美元。</blockquote></p><p> “While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p><p><blockquote>“美国食品和药物管理局代理局长珍妮特-伍德科克（Janet Woodcock）说：”虽然我完全支持该中心最近批准该疗法的决定，但我承认，包括美国食品和药物管理局内部在内，对这一决定有不同的意见，围绕我们的审查程序和我们为支持批准而考虑的数据可能会继续存在疑问。“最终，美国食品和药物管理局一组经验丰富的医学审查员得出结论，有足够的证据通过加速审批途径批准阿尔茨海默氏症疗法。”</blockquote></p><p> Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p><p><blockquote>支持者说，美国食品和药物管理局的决定为那些缺乏任何有望减缓阿尔茨海默氏症进展的药物的患者提供了一条生命线，这一决定可能会刺激更多更好的药物的开发。</blockquote></p><p> The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p><p><blockquote>该机构通常会在做出决定后发布批准文件，尽管通常不会像这次那么快。这 83 页的备忘录似乎是 FDA 审议的一部分，主要反映了高层官员的交流。</blockquote></p><p> Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p><p><blockquote>一份内部文件显示，美国食品和药物管理局（FDA）的生物统计学审查员特里斯坦-马西（Tristan Massie）“不同意所有数据提供了足够的证据来支持aducanumab治疗阿尔茨海默病的疗效，因此不建议批准”。</blockquote></p><p> Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p><p><blockquote>美国食品和药物管理局（FDA）最高级别的药物评估官员帕特里齐亚-卡瓦佐尼（Patrizia Cavazzoni）在另一份备忘录中写道，该机构的药物生物统计办公室 “为其建议提供了文件，即申请中没有提供实质性的有效性证据”。</blockquote></p><p> That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p><p><blockquote>该办公室的完整异议分析并未包含在周二提供的材料中，但部分内容包含在内。</blockquote></p><p> Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p><p><blockquote>尽管有人反对，卡瓦佐尼博士还是写道，百健公司已经满足了 “加速批准 ”的要求，这是一种监管许可，允许一种药物在临床益处仍存在不确定性的情况下上市，只要该药物满足了严重疾病未得到满足的需求，并且对疾病的生物体征产生了影响。</blockquote></p><p> Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p><p><blockquote>Cavazzoni 博士写道，Aduhelm 之所以符合这一标准，是因为它能减少一种叫做淀粉样蛋白的粘性物质，而淀粉样蛋白 “很有可能预测临床益处”。</blockquote></p><p> Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p><p><blockquote>一些医生和科学家说，针对淀粉样斑块尚未被证明可以减缓阿尔茨海默氏症的进展。建议美国食品和药物管理局拒绝该药物的顾问小组的一些成员以该机构的批准为由辞去了委员会职务。</blockquote></p><p> Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p><p><blockquote>百健将 Aduhelm 的价格列为每年 56,000 美元，患者和医疗保险也可能面临检测费用。</blockquote></p><p> About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p><p><blockquote>约有 600 万美国人患有阿尔茨海默氏症，这是一种会剥夺人们记忆和认知能力的进行性疾病。百健表示，其中多达200万人可能会从这种药物中受益。</blockquote></p><p> The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p><p><blockquote>美国食品和药物管理局的批准使百健的股价飙升。该公司表示，预计今年该药物的收入将微乎其微，部分原因是管理该药物的后勤挑战，但销售额将在明年开始增长。</blockquote></p><p> Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p><p><blockquote>根据 FactSet 的数据，分析师预计 2022 年销售额为 9.463 亿美元。预计 2026 年销售额将增长至 52 亿美元。</blockquote></p><p> The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p><p><blockquote>备忘录显示，美国食品和药物管理局官员正试图在 Aduhelm 的研究数据与阿尔茨海默氏症患者及其家人尝试任何可能有帮助的新疗法的愿望之间取得平衡。</blockquote></p><p></p><p> “There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p><p><blockquote>“斯坦因博士写道：”临床获益仍存在不确定性。但他写道，如果美国食品和药物管理局等待该公司完成另一项临床研究，“任何批准都将在多年的延迟之后进行”，患者 “可能会遭受不可逆转的大脑神经元、认知功能和记忆力丧失”。</blockquote></p><p> The FDA said it plans to release more documents regarding its decision making as early as next week.</p><p><blockquote>FDA表示，计划最早下周发布更多有关其决策的文件。</blockquote></p><p> The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p><p><blockquote>美国食品和药物管理局的批准主要基于百健公司启动的两项大型 3 期临床试验，以证明其药物有助于减缓早期阿尔茨海默氏症患者的认知能力下降。</blockquote></p><p> In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p><p><blockquote>2019 年 3 月，在独立监测委员会得出结论该药物不太可能帮助患者后，该公司提前停止了研究。</blockquote></p><p> Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p><p><blockquote>然而，七个月后，该公司做出了令人惊讶的逆转，并表示在对研究停止后获得的试验数据进行额外分析后，现在正计划寻求 FDA 的批准。该公司表示，其分析发现该药物在一项研究中取得了成功，但在第二项研究中失败。</blockquote></p><p> The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p><p><blockquote>美国食品和药物管理局的备忘录提供了一些关于百健转变的新细节。根据一份 “摘要备忘录 ”文件，2019 年 6 月，该公司会见了 FDA 官员，双方一致认为不应停止研究。</blockquote></p><p> At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p><p><blockquote>在会议上，FDA 官员建议百健进一步分析这些研究，以了解尽管试验停止且结果相互矛盾，但是否仍然有可能从数据中得出结论。</blockquote></p><p> Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p><p><blockquote>根据备忘录，几个月后，即 2019 年 10 月，该机构和公司再次会面，并一致认为这些研究仍可用于评估药物的有效性。</blockquote></p><p> The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p><p><blockquote>第二天，即 10 月 22 日，百健宣布将寻求该药物的批准，从而推高其股价，并为其市值增加数十亿美元。</blockquote></p><p> The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p><p><blockquote>百健公司首席执行官米歇尔-沃纳索斯（Michel Vounatsos）当时在接受采访时说，几个月来，公司一直在悄悄地重新审查这些数据，但直到最近一次与美国食品及药物管理局官员会面，公司才有信心继续前进。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管有一些工作人员的担忧，FDA 还是批准了百健阿尔茨海默病药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管有一些工作人员的担忧，FDA 还是批准了百健阿尔茨海默病药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">WSJ</strong><span class=\"h-time small\">2021-06-23 13:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p><p><blockquote>美国根据新公布的内部备忘录，美国食品和药物管理局批准了几十年来首个阿尔茨海默氏症新药，但该机构的统计人员表示反对，称没有足够的证据支持批准。</blockquote></p><p> In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p><p><blockquote>在周二发布的内部备忘录中，FDA 官员讨论了是否批准 fromBiogenInc.BIIB-1.71% 的药物，因为该机构药物统计办公室表示，临床试验数据达不到将新产品推向市场通常所需的证据。</blockquote></p><p> Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p><p><blockquote>根据备忘录，最终，高级官员决定，表明该药物有效的证据虽然不确定，但足以让医生和患者自行决定是否服用该药物。</blockquote></p><p> “FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p><p><blockquote>“美国食品和药物管理局新药办公室主任彼得-斯坦（Peter Stein）在一份备忘录中详细说明了他对批准 aducanumab 的支持，他写道：”美国食品和药物管理局新药办公室主任彼得-斯坦（Peter Stein）在一份备忘录中写道。“与此同时，[阿尔茨海默氏症]患者患有严重的、进行性的、最终致命的疾病，他们迫切需要治疗”。</blockquote></p><p> The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p><p><blockquote>FDA 公开了其内部审议，因为它面临一些医生和科学家对 6 月 7 日批准名为 Aduhelm 的药物的批评。</blockquote></p><p> The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p><p><blockquote>批评者称，FDA忽视了制药商通常遵守的科学标准，并可能促使联邦政府在一种可能无效的药物上花费数十亿美元。</blockquote></p><p> “While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p><p><blockquote>“美国食品和药物管理局代理局长珍妮特-伍德科克（Janet Woodcock）说：”虽然我完全支持该中心最近批准该疗法的决定，但我承认，包括美国食品和药物管理局内部在内，对这一决定有不同的意见，围绕我们的审查程序和我们为支持批准而考虑的数据可能会继续存在疑问。“最终，美国食品和药物管理局一组经验丰富的医学审查员得出结论，有足够的证据通过加速审批途径批准阿尔茨海默氏症疗法。”</blockquote></p><p> Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p><p><blockquote>支持者说，美国食品和药物管理局的决定为那些缺乏任何有望减缓阿尔茨海默氏症进展的药物的患者提供了一条生命线，这一决定可能会刺激更多更好的药物的开发。</blockquote></p><p> The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p><p><blockquote>该机构通常会在做出决定后发布批准文件，尽管通常不会像这次那么快。这 83 页的备忘录似乎是 FDA 审议的一部分，主要反映了高层官员的交流。</blockquote></p><p> Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p><p><blockquote>一份内部文件显示，美国食品和药物管理局（FDA）的生物统计学审查员特里斯坦-马西（Tristan Massie）“不同意所有数据提供了足够的证据来支持aducanumab治疗阿尔茨海默病的疗效，因此不建议批准”。</blockquote></p><p> Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p><p><blockquote>美国食品和药物管理局（FDA）最高级别的药物评估官员帕特里齐亚-卡瓦佐尼（Patrizia Cavazzoni）在另一份备忘录中写道，该机构的药物生物统计办公室 “为其建议提供了文件，即申请中没有提供实质性的有效性证据”。</blockquote></p><p> That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p><p><blockquote>该办公室的完整异议分析并未包含在周二提供的材料中，但部分内容包含在内。</blockquote></p><p> Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p><p><blockquote>尽管有人反对，卡瓦佐尼博士还是写道，百健公司已经满足了 “加速批准 ”的要求，这是一种监管许可，允许一种药物在临床益处仍存在不确定性的情况下上市，只要该药物满足了严重疾病未得到满足的需求，并且对疾病的生物体征产生了影响。</blockquote></p><p> Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p><p><blockquote>Cavazzoni 博士写道，Aduhelm 之所以符合这一标准，是因为它能减少一种叫做淀粉样蛋白的粘性物质，而淀粉样蛋白 “很有可能预测临床益处”。</blockquote></p><p> Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p><p><blockquote>一些医生和科学家说，针对淀粉样斑块尚未被证明可以减缓阿尔茨海默氏症的进展。建议美国食品和药物管理局拒绝该药物的顾问小组的一些成员以该机构的批准为由辞去了委员会职务。</blockquote></p><p> Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p><p><blockquote>百健将 Aduhelm 的价格列为每年 56,000 美元，患者和医疗保险也可能面临检测费用。</blockquote></p><p> About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p><p><blockquote>约有 600 万美国人患有阿尔茨海默氏症，这是一种会剥夺人们记忆和认知能力的进行性疾病。百健表示，其中多达200万人可能会从这种药物中受益。</blockquote></p><p> The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p><p><blockquote>美国食品和药物管理局的批准使百健的股价飙升。该公司表示，预计今年该药物的收入将微乎其微，部分原因是管理该药物的后勤挑战，但销售额将在明年开始增长。</blockquote></p><p> Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p><p><blockquote>根据 FactSet 的数据，分析师预计 2022 年销售额为 9.463 亿美元。预计 2026 年销售额将增长至 52 亿美元。</blockquote></p><p> The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p><p><blockquote>备忘录显示，美国食品和药物管理局官员正试图在 Aduhelm 的研究数据与阿尔茨海默氏症患者及其家人尝试任何可能有帮助的新疗法的愿望之间取得平衡。</blockquote></p><p></p><p> “There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p><p><blockquote>“斯坦因博士写道：”临床获益仍存在不确定性。但他写道，如果美国食品和药物管理局等待该公司完成另一项临床研究，“任何批准都将在多年的延迟之后进行”，患者 “可能会遭受不可逆转的大脑神经元、认知功能和记忆力丧失”。</blockquote></p><p> The FDA said it plans to release more documents regarding its decision making as early as next week.</p><p><blockquote>FDA表示，计划最早下周发布更多有关其决策的文件。</blockquote></p><p> The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p><p><blockquote>美国食品和药物管理局的批准主要基于百健公司启动的两项大型 3 期临床试验，以证明其药物有助于减缓早期阿尔茨海默氏症患者的认知能力下降。</blockquote></p><p> In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p><p><blockquote>2019 年 3 月，在独立监测委员会得出结论该药物不太可能帮助患者后，该公司提前停止了研究。</blockquote></p><p> Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p><p><blockquote>然而，七个月后，该公司做出了令人惊讶的逆转，并表示在对研究停止后获得的试验数据进行额外分析后，现在正计划寻求 FDA 的批准。该公司表示，其分析发现该药物在一项研究中取得了成功，但在第二项研究中失败。</blockquote></p><p> The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p><p><blockquote>美国食品和药物管理局的备忘录提供了一些关于百健转变的新细节。根据一份 “摘要备忘录 ”文件，2019 年 6 月，该公司会见了 FDA 官员，双方一致认为不应停止研究。</blockquote></p><p> At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p><p><blockquote>在会议上，FDA 官员建议百健进一步分析这些研究，以了解尽管试验停止且结果相互矛盾，但是否仍然有可能从数据中得出结论。</blockquote></p><p> Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p><p><blockquote>根据备忘录，几个月后，即 2019 年 10 月，该机构和公司再次会面，并一致认为这些研究仍可用于评估药物的有效性。</blockquote></p><p> The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p><p><blockquote>第二天，即 10 月 22 日，百健宣布将寻求该药物的批准，从而推高其股价，并为其市值增加数十亿美元。</blockquote></p><p> The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p><p><blockquote>百健公司首席执行官米歇尔-沃纳索斯（Michel Vounatsos）当时在接受采访时说，几个月来，公司一直在悄悄地重新审查这些数据，但直到最近一次与美国食品及药物管理局官员会面，公司才有信心继续前进。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2\">WSJ</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174011543","content_text":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.\nIn the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.\nUltimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.\n“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”\nThe FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.\nThe critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.\n“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”\nSupporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.\nThe agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.\nTristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.\nPatrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”\nThat office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.\nDespite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.\nDr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”\nSome doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.\nBiogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.\nAbout six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.\nThe FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.\nAnalysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.\nThe memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.\n“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.\nThe FDA said it plans to release more documents regarding its decision making as early as next week.\nThe FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.\nIn March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.\nSeven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.\nThe FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.\nAt the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.\nSeveral months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.\nThe following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.\nThe company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":3669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":123566429,"gmtCreate":1624429967061,"gmtModify":1634006224487,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123566429","repostId":"114899451","repostType":1,"repost":{"id":114899451,"gmtCreate":1623063308869,"gmtModify":1631884627596,"author":{"id":"36984908995200","authorId":"36984908995200","name":"小虎活动","avatar":"https://static.tigerbbs.com/9e396d03155923b283948d2dec9191f8","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"36984908995200","authorIdStr":"36984908995200"},"themes":[],"title":"【老虎7周年】集卡瓜分百万奖金","htmlText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> &#x1;如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。&#x1;如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 &#x1; &#x1;如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。&#x1; 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP &gt; 我的 &gt; 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","listText":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ <a href=\"https://www.itiger.com/activity/market/2021/7th-anniversary?lang=zh_CN\" target=\"_blank\">戳我即可参与活动</a> &#x1;如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。&#x1;如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 &#x1; &#x1;如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。&#x1; 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP &gt; 我的 &gt; 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","text":"老虎7周年给大家发福利了，集齐TIGER五个字母即有机会瓜分百万奖金，你准备好了吗？ 戳我即可参与活动 \u0001如何参与？ 用户可通过完成活动页面展示的当日任务列表来获得字母卡，每完成一个任务即可随机获得一个字母，用户集齐“TIGER”五个字母即可参与瓜分百万股票代金券，每个用户单日最多可获得20张字母卡（不包括好友赠予和魔法卡）。 用户在活动期间邀请累计7名好友完成注册并开户（注册时间和开户时间均在活动期间），即可获得一张魔法卡（每人仅可获得一张魔法卡）。魔法卡可用于兑换TIGER中的任意一个字母。\u0001如果用户的某一字母卡数量为0，则字母卡为灰色，用户可通过点击灰色的字母卡向好友索要卡片；如果用户的字母卡数量大于0，则字母卡为彩色，用户可通过点击彩色的字母卡向好友赠送卡片。当用户集齐TIGER之后将无法再索要卡片或者赠送卡片。 \u0001 \u0001如何获得奖励？ 用户可在2021年7月1日至2021年7月2日期间进行开奖，所有集齐TIGER的客户可点击活动页面的“开奖”按钮，即可查看自己瓜分到的股票代金券奖励。在开奖时间段内未点击开奖的用户将无法获得奖励。\u0001 奖励发放： 股票代金券将在开奖后的1个工作日内发放至用户的奖励中心，用户需要在奖励发放后的20天内前往【Tiger Trade APP > 我的 > 活动奖励】领取，过期未领取的奖励将自动失效。 重要提示： 本次7周年活动涉及不同国家和地区，由于各地区的监管要求不同，不同地区的活动奖励会有所区别。欲知详情，请点击下方活动链接，登陆您的账号，并点击“活动规则“查看详情。","images":[{"img":"https://static.tigerbbs.com/ab28db31a19b458d604a8bf02becddd3","width":"415","height":"125"},{"img":"https://static.tigerbbs.com/5227ebb594fe55b532c840acef147d7b","width":"415","height":"495"},{"img":"https://static.tigerbbs.com/92e88357b534f504b3088bc22f577a83","width":"415","height":"326"}],"top":1,"highlighted":2,"essential":1,"paper":2,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/114899451","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":8,"langContent":"CN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":3872,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123518556,"gmtCreate":1624429005975,"gmtModify":1634006232788,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123518556","repostId":"2145671770","repostType":2,"isVote":1,"tweetType":1,"viewCount":3903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123510136,"gmtCreate":1624428873625,"gmtModify":1634006234187,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123510136","repostId":"1123710128","repostType":4,"repost":{"id":"1123710128","kind":"news","pubTimestamp":1624406277,"share":"https://www.laohunote.com/m/news/1123710128?lang=zh_CN&edition=full","pubTime":"2021-06-23 07:57","market":"us","language":"en","title":"EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123710128","media":"Bloomberg","summary":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than prev","content":"<p><div> (Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission ...</p><p><blockquote><div>（彭博社）——随着更严格的法规和日益增长的兴趣推动了对零排放的需求，全球电动汽车的霸主地位将于2033年到来，比之前预期提前了五年……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页连接</a></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 07:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> (Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission ...</p><p><blockquote><div>（彭博社）——随着更严格的法规和日益增长的兴趣推动了对零排放的需求，全球电动汽车的霸主地位将于2033年到来，比之前预期提前了五年……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123710128","content_text":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.\nConsultant Ernst & Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.\nStrict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.\nThe U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.\n“The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”\nThere also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.\n‘More Appealing’\n“Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”\nThe EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.\n“The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.\nAdditionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.\nEurope is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.\nVehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.","news_type":1,"symbols_score_info":{"TSLA":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":3618,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597682,"gmtCreate":1624428375546,"gmtModify":1634006238087,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"title":"","htmlText":"What","listText":"What","text":"What","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597682","repostId":"1123710128","repostType":4,"repost":{"id":"1123710128","kind":"news","pubTimestamp":1624406277,"share":"https://www.laohunote.com/m/news/1123710128?lang=zh_CN&edition=full","pubTime":"2021-06-23 07:57","market":"us","language":"en","title":"EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1123710128","media":"Bloomberg","summary":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than prev","content":"<p><div> (Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission ...</p><p><blockquote><div>（彭博社）——随着更严格的法规和日益增长的兴趣推动了对零排放的需求，全球电动汽车的霸主地位将于2033年到来，比之前预期提前了五年……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页连接</a></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEVs Seen Reaching Sales Supremacy by 2033, Faster Than Expected<blockquote>电动汽车预计到 2033 年将比预期更快地占据销售霸主地位</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 07:57</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> (Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission ...</p><p><blockquote><div>（彭博社）——随着更严格的法规和日益增长的兴趣推动了对零排放的需求，全球电动汽车的霸主地位将于2033年到来，比之前预期提前了五年……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉"},"source_url":"https://finance.yahoo.com/news/evs-seen-reaching-sales-supremacy-230100585.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1123710128","content_text":"(Bloomberg) -- Global electric vehicle supremacy will arrive by 2033 -- five years earlier than previously expected -- as tougher regulations and rising interest drive demand for zero-emission transportation, according to a new study.\nConsultant Ernst & Young LLP now sees EV sales outpacing fossil fuel-burners in 12 years in Europe, China and the U.S. -- the world’s largest auto markets. And by 2045, non-EV sales are seen plummeting to less than 1% of the global car market, EY forecast using an AI-powered prediction tool.\nStrict government mandates to combat climate change are driving demand in Europe and China, where automakers and consumers face rising financial penalties for selling and buying traditional gasoline and diesel-fueled cars. EY sees Europe leading the charge to electric, with zero-emission models outselling all other propulsion systems by 2028. That tipping point will arrive in China in 2033 and in the U.S. in 2036, EY predicts.\nThe U.S. lags the world’s other leading markets because fuel-economy regulations were eased during President Donald Trump’s administration. Since taking office in January, President Joe Biden has rejoined the Paris Climate Accord and proposed spending $174 billion to accelerate the shift to EVs, including installing a half-million charging stations across the country.\n“The regulatory environment from the Biden administration we view as a big contributor, because he has ambitious targets,” Randy Miller, EY’s global advanced manufacturing and mobility leader, said in an interview. “That impact in the Americas will have a supercharging effect.”\nThere also is a growing consumer appetite for EVs, from Tesla Inc.’s hot-selling Model 3 to new electric models coming from legacy automakers, such as General Motors Co.’s battery-powered Hummer truck and Ford Motor Co.’s F-150 Lightning pickup. Investments in battery powered models now top $230 billion from the world’s automakers, according to consultant AlixPartners.\n‘More Appealing’\n“Many more models that are much more appealing are coming out,” Miller said. “You factor that with the incentives, and those are the raw ingredients that are driving this more optimistic view.”\nThe EY study also sees the millennial generation, now in their late 20s and 30s, as helping to propel EV adoption. Those consumers, driven by a coronavirus-influenced rejection of ride-sharing and public transportation, are embracing car ownership. And 30% of them want to drive an EV, Miller said.\n“The view from the millennials that we’re seeing is clearly more inclination to want to buy EVs,” Miller said.\nAdditionally, the combination of government purchase incentives for EVs and proposed bans on internal combustion engines in cities and states are accelerating the adoption of battery-powered vehicles.\nEurope is forecast to lead in EV sales volumes until 2031, when China will become the world’s top market for electric vehicles.\nVehicles powered by gasoline and diesel are still predicted to make up around two-thirds of all light vehicle registrations in 2025, but that will mark a 12 percentage-point decrease from five years earlier. By 2030, EY predicts that non-EV cars will account for less than half of overall light vehicle registrations.","news_type":1,"symbols_score_info":{"TSLA":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":1826,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123597355,"gmtCreate":1624428362077,"gmtModify":1634006238208,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Yums","listText":"Yums","text":"Yums","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123597355","repostId":"1126010678","repostType":4,"repost":{"id":"1126010678","kind":"news","pubTimestamp":1624412603,"share":"https://www.laohunote.com/m/news/1126010678?lang=zh_CN&edition=full","pubTime":"2021-06-23 09:43","market":"us","language":"en","title":"Krispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转移到线上，Krispy Kreme 寻求 6.4 亿美元 IPO</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1126010678","media":"Bloomberg","summary":"(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise a","content":"<p><div> (Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering. The company said in a filing Tuesday that it ...</p><p><blockquote><div>（彭博社）——JAB Holdings BV 旗下的甜甜圈连锁店 Krispy Kreme Inc. 正寻求在首次公开募股中筹集高达 6.4 亿美元的资金。该公司在周二的一份文件中表示……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">网页连接</a></blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Krispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转移到线上，Krispy Kreme 寻求 6.4 亿美元 IPO</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKrispy Kreme Seeks $640 Million in IPO as Sales Move Online<blockquote>随着销售转移到线上，Krispy Kreme 寻求 6.4 亿美元 IPO</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-06-23 09:43</span>\n</p>\n</h4>\n</header>\n<article>\n<p><div> (Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering. The company said in a filing Tuesday that it ...</p><p><blockquote><div>（彭博社）——JAB Holdings BV 旗下的甜甜圈连锁店 Krispy Kreme Inc. 正寻求在首次公开募股中筹集高达 6.4 亿美元的资金。该公司在周二的一份文件中表示……</div></blockquote></p><p>  <a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">网页链接</a>  </div> </p><p><blockquote><a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">网页连接</a></blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DNUT":"Krispy Kreme, Inc."},"source_url":"https://finance.yahoo.com/news/krispy-kreme-sets-price-range-154753866.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1126010678","content_text":"(Bloomberg) -- Krispy Kreme Inc., the doughnut chain owned by JAB Holdings BV, is seeking to raise as much as $640 million in an initial public offering.\nThe company said in a filing Tuesday that it plans to sell almost 27 million shares for $21 to $24 apiece. At the top end of the range, Krispy Kreme would have a market value of $3.86 billion based on the outstanding shares listed in the filing with the U.S. Securities and Exchange Commission.\nAmid photos of doughnuts dripping with sugary glaze and dotted with sprinkles, the company declares in the filing that its purpose is “to touch and enhance lives through the joy of Krispy Kreme.”\nSince its acquisition by Luxembourg-based conglomerate JAB in 2016, Krispy Kreme has expanded its online presence. Its e-commerce business now accounts for close to a fifth of sales in the U.S., fueled by its Insomnia Cookies delivery concept.\nNet revenue for the Charlotte, North Carolina-based chain rose 23% to $322 million in the quarter ended April 4, according to the filing. Its net loss for the quarter shrunk from $11 million in 2020 to $378,000 this year.\nKrispy Kreme plans to use proceeds from the IPO to pay down debt and buy back shares from certain executives, as well as for general corporate purposes, according to the filing. JAB will continue to own almost 78% of the company’s shares after the IPO.\nThe offering is being led by JPMorgan Chase & Co., Morgan Stanley, Bank of America Corp. and Citigroup Inc. The company plans to list on the Nasdaq Global Select Market under the symbol DNUT.","news_type":1,"symbols_score_info":{"DNUT":0.9}},"isVote":1,"tweetType":1,"viewCount":3855,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123594843,"gmtCreate":1624428337982,"gmtModify":1634006238572,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123594843","repostId":"2145057786","repostType":4,"isVote":1,"tweetType":1,"viewCount":3903,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123595713,"gmtCreate":1624428311132,"gmtModify":1634006238814,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Cool","listText":"Cool","text":"Cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123595713","repostId":"2145066250","repostType":4,"isVote":1,"tweetType":1,"viewCount":3363,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592750,"gmtCreate":1624428287070,"gmtModify":1634006239664,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592750","repostId":"1192380860","repostType":4,"isVote":1,"tweetType":1,"viewCount":2233,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":123592828,"gmtCreate":1624428233064,"gmtModify":1634006240151,"author":{"id":"3584774162933077","authorId":"3584774162933077","name":"Babaluke","avatar":"https://static.tigerbbs.com/cf1bdc263bcb63f2412eb36286eaedda","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3584774162933077","authorIdStr":"3584774162933077"},"themes":[],"title":"","htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/123592828","repostId":"1174011543","repostType":4,"repost":{"id":"1174011543","kind":"news","pubTimestamp":1624425845,"share":"https://www.laohunote.com/m/news/1174011543?lang=zh_CN&edition=full","pubTime":"2021-06-23 13:24","market":"us","language":"en","title":"FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管有一些工作人员的担忧，FDA 还是批准了百健阿尔茨海默病药物</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1174011543","media":"WSJ","summary":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the obje","content":"<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p><p><blockquote>美国根据新公布的内部备忘录，美国食品和药物管理局批准了几十年来首个阿尔茨海默氏症新药，但该机构的统计人员表示反对，称没有足够的证据支持批准。</blockquote></p><p> In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p><p><blockquote>在周二发布的内部备忘录中，FDA 官员讨论了是否批准 fromBiogenInc.BIIB-1.71% 的药物，因为该机构药物统计办公室表示，临床试验数据达不到将新产品推向市场通常所需的证据。</blockquote></p><p> Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p><p><blockquote>根据备忘录，最终，高级官员决定，表明该药物有效的证据虽然不确定，但足以让医生和患者自行决定是否服用该药物。</blockquote></p><p> “FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p><p><blockquote>“美国食品和药物管理局新药办公室主任彼得-斯坦（Peter Stein）在一份备忘录中详细说明了他对批准 aducanumab 的支持，他写道：”美国食品和药物管理局新药办公室主任彼得-斯坦（Peter Stein）在一份备忘录中写道。“与此同时，[阿尔茨海默氏症]患者患有严重的、进行性的、最终致命的疾病，他们迫切需要治疗”。</blockquote></p><p> The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p><p><blockquote>FDA 公开了其内部审议，因为它面临一些医生和科学家对 6 月 7 日批准名为 Aduhelm 的药物的批评。</blockquote></p><p> The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p><p><blockquote>批评者称，FDA忽视了制药商通常遵守的科学标准，并可能促使联邦政府在一种可能无效的药物上花费数十亿美元。</blockquote></p><p> “While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p><p><blockquote>“美国食品和药物管理局代理局长珍妮特-伍德科克（Janet Woodcock）说：”虽然我完全支持该中心最近批准该疗法的决定，但我承认，包括美国食品和药物管理局内部在内，对这一决定有不同的意见，围绕我们的审查程序和我们为支持批准而考虑的数据可能会继续存在疑问。“最终，美国食品和药物管理局一组经验丰富的医学审查员得出结论，有足够的证据通过加速审批途径批准阿尔茨海默氏症疗法。”</blockquote></p><p> Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p><p><blockquote>支持者说，美国食品和药物管理局的决定为那些缺乏任何有望减缓阿尔茨海默氏症进展的药物的患者提供了一条生命线，这一决定可能会刺激更多更好的药物的开发。</blockquote></p><p> The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p><p><blockquote>该机构通常会在做出决定后发布批准文件，尽管通常不会像这次那么快。这 83 页的备忘录似乎是 FDA 审议的一部分，主要反映了高层官员的交流。</blockquote></p><p> Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p><p><blockquote>一份内部文件显示，美国食品和药物管理局（FDA）的生物统计学审查员特里斯坦-马西（Tristan Massie）“不同意所有数据提供了足够的证据来支持aducanumab治疗阿尔茨海默病的疗效，因此不建议批准”。</blockquote></p><p> Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p><p><blockquote>美国食品和药物管理局（FDA）最高级别的药物评估官员帕特里齐亚-卡瓦佐尼（Patrizia Cavazzoni）在另一份备忘录中写道，该机构的药物生物统计办公室 “为其建议提供了文件，即申请中没有提供实质性的有效性证据”。</blockquote></p><p> That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p><p><blockquote>该办公室的完整异议分析并未包含在周二提供的材料中，但部分内容包含在内。</blockquote></p><p> Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p><p><blockquote>尽管有人反对，卡瓦佐尼博士还是写道，百健公司已经满足了 “加速批准 ”的要求，这是一种监管许可，允许一种药物在临床益处仍存在不确定性的情况下上市，只要该药物满足了严重疾病未得到满足的需求，并且对疾病的生物体征产生了影响。</blockquote></p><p> Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p><p><blockquote>Cavazzoni 博士写道，Aduhelm 之所以符合这一标准，是因为它能减少一种叫做淀粉样蛋白的粘性物质，而淀粉样蛋白 “很有可能预测临床益处”。</blockquote></p><p> Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p><p><blockquote>一些医生和科学家说，针对淀粉样斑块尚未被证明可以减缓阿尔茨海默氏症的进展。建议美国食品和药物管理局拒绝该药物的顾问小组的一些成员以该机构的批准为由辞去了委员会职务。</blockquote></p><p> Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p><p><blockquote>百健将 Aduhelm 的价格列为每年 56,000 美元，患者和医疗保险也可能面临检测费用。</blockquote></p><p> About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p><p><blockquote>约有 600 万美国人患有阿尔茨海默氏症，这是一种会剥夺人们记忆和认知能力的进行性疾病。百健表示，其中多达200万人可能会从这种药物中受益。</blockquote></p><p> The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p><p><blockquote>美国食品和药物管理局的批准使百健的股价飙升。该公司表示，预计今年该药物的收入将微乎其微，部分原因是管理该药物的后勤挑战，但销售额将在明年开始增长。</blockquote></p><p> Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p><p><blockquote>根据 FactSet 的数据，分析师预计 2022 年销售额为 9.463 亿美元。预计 2026 年销售额将增长至 52 亿美元。</blockquote></p><p> The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p><p><blockquote>备忘录显示，美国食品和药物管理局官员正试图在 Aduhelm 的研究数据与阿尔茨海默氏症患者及其家人尝试任何可能有帮助的新疗法的愿望之间取得平衡。</blockquote></p><p></p><p> “There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p><p><blockquote>“斯坦因博士写道：”临床获益仍存在不确定性。但他写道，如果美国食品和药物管理局等待该公司完成另一项临床研究，“任何批准都将在多年的延迟之后进行”，患者 “可能会遭受不可逆转的大脑神经元、认知功能和记忆力丧失”。</blockquote></p><p> The FDA said it plans to release more documents regarding its decision making as early as next week.</p><p><blockquote>FDA表示，计划最早下周发布更多有关其决策的文件。</blockquote></p><p> The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p><p><blockquote>美国食品和药物管理局的批准主要基于百健公司启动的两项大型 3 期临床试验，以证明其药物有助于减缓早期阿尔茨海默氏症患者的认知能力下降。</blockquote></p><p> In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p><p><blockquote>2019 年 3 月，在独立监测委员会得出结论该药物不太可能帮助患者后，该公司提前停止了研究。</blockquote></p><p> Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p><p><blockquote>然而，七个月后，该公司做出了令人惊讶的逆转，并表示在对研究停止后获得的试验数据进行额外分析后，现在正计划寻求 FDA 的批准。该公司表示，其分析发现该药物在一项研究中取得了成功，但在第二项研究中失败。</blockquote></p><p> The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p><p><blockquote>美国食品和药物管理局的备忘录提供了一些关于百健转变的新细节。根据一份 “摘要备忘录 ”文件，2019 年 6 月，该公司会见了 FDA 官员，双方一致认为不应停止研究。</blockquote></p><p> At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p><p><blockquote>在会议上，FDA 官员建议百健进一步分析这些研究，以了解尽管试验停止且结果相互矛盾，但是否仍然有可能从数据中得出结论。</blockquote></p><p> Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p><p><blockquote>根据备忘录，几个月后，即 2019 年 10 月，该机构和公司再次会面，并一致认为这些研究仍可用于评估药物的有效性。</blockquote></p><p> The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p><p><blockquote>第二天，即 10 月 22 日，百健宣布将寻求该药物的批准，从而推高其股价，并为其市值增加数十亿美元。</blockquote></p><p> The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p><p><blockquote>百健公司首席执行官米歇尔-沃纳索斯（Michel Vounatsos）当时在接受采访时说，几个月来，公司一直在悄悄地重新审查这些数据，但直到最近一次与美国食品及药物管理局官员会面，公司才有信心继续前进。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管有一些工作人员的担忧，FDA 还是批准了百健阿尔茨海默病药物</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Approved Biogen Alzheimer’s Drug Despite Some Staff Concerns<blockquote>尽管有一些工作人员的担忧，FDA 还是批准了百健阿尔茨海默病药物</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">WSJ</strong><span class=\"h-time small\">2021-06-23 13:24</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.</p><p><blockquote>美国根据新公布的内部备忘录，美国食品和药物管理局批准了几十年来首个阿尔茨海默氏症新药，但该机构的统计人员表示反对，称没有足够的证据支持批准。</blockquote></p><p> In the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.</p><p><blockquote>在周二发布的内部备忘录中，FDA 官员讨论了是否批准 fromBiogenInc.BIIB-1.71% 的药物，因为该机构药物统计办公室表示，临床试验数据达不到将新产品推向市场通常所需的证据。</blockquote></p><p> Ultimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.</p><p><blockquote>根据备忘录，最终，高级官员决定，表明该药物有效的证据虽然不确定，但足以让医生和患者自行决定是否服用该药物。</blockquote></p><p> “FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”</p><p><blockquote>“美国食品和药物管理局新药办公室主任彼得-斯坦（Peter Stein）在一份备忘录中详细说明了他对批准 aducanumab 的支持，他写道：”美国食品和药物管理局新药办公室主任彼得-斯坦（Peter Stein）在一份备忘录中写道。“与此同时，[阿尔茨海默氏症]患者患有严重的、进行性的、最终致命的疾病，他们迫切需要治疗”。</blockquote></p><p> The FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.</p><p><blockquote>FDA 公开了其内部审议，因为它面临一些医生和科学家对 6 月 7 日批准名为 Aduhelm 的药物的批评。</blockquote></p><p> The critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.</p><p><blockquote>批评者称，FDA忽视了制药商通常遵守的科学标准，并可能促使联邦政府在一种可能无效的药物上花费数十亿美元。</blockquote></p><p> “While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”</p><p><blockquote>“美国食品和药物管理局代理局长珍妮特-伍德科克（Janet Woodcock）说：”虽然我完全支持该中心最近批准该疗法的决定，但我承认，包括美国食品和药物管理局内部在内，对这一决定有不同的意见，围绕我们的审查程序和我们为支持批准而考虑的数据可能会继续存在疑问。“最终，美国食品和药物管理局一组经验丰富的医学审查员得出结论，有足够的证据通过加速审批途径批准阿尔茨海默氏症疗法。”</blockquote></p><p> Supporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.</p><p><blockquote>支持者说，美国食品和药物管理局的决定为那些缺乏任何有望减缓阿尔茨海默氏症进展的药物的患者提供了一条生命线，这一决定可能会刺激更多更好的药物的开发。</blockquote></p><p> The agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.</p><p><blockquote>该机构通常会在做出决定后发布批准文件，尽管通常不会像这次那么快。这 83 页的备忘录似乎是 FDA 审议的一部分，主要反映了高层官员的交流。</blockquote></p><p> Tristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.</p><p><blockquote>一份内部文件显示，美国食品和药物管理局（FDA）的生物统计学审查员特里斯坦-马西（Tristan Massie）“不同意所有数据提供了足够的证据来支持aducanumab治疗阿尔茨海默病的疗效，因此不建议批准”。</blockquote></p><p> Patrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”</p><p><blockquote>美国食品和药物管理局（FDA）最高级别的药物评估官员帕特里齐亚-卡瓦佐尼（Patrizia Cavazzoni）在另一份备忘录中写道，该机构的药物生物统计办公室 “为其建议提供了文件，即申请中没有提供实质性的有效性证据”。</blockquote></p><p> That office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.</p><p><blockquote>该办公室的完整异议分析并未包含在周二提供的材料中，但部分内容包含在内。</blockquote></p><p> Despite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.</p><p><blockquote>尽管有人反对，卡瓦佐尼博士还是写道，百健公司已经满足了 “加速批准 ”的要求，这是一种监管许可，允许一种药物在临床益处仍存在不确定性的情况下上市，只要该药物满足了严重疾病未得到满足的需求，并且对疾病的生物体征产生了影响。</blockquote></p><p> Dr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”</p><p><blockquote>Cavazzoni 博士写道，Aduhelm 之所以符合这一标准，是因为它能减少一种叫做淀粉样蛋白的粘性物质，而淀粉样蛋白 “很有可能预测临床益处”。</blockquote></p><p> Some doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.</p><p><blockquote>一些医生和科学家说，针对淀粉样斑块尚未被证明可以减缓阿尔茨海默氏症的进展。建议美国食品和药物管理局拒绝该药物的顾问小组的一些成员以该机构的批准为由辞去了委员会职务。</blockquote></p><p> Biogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.</p><p><blockquote>百健将 Aduhelm 的价格列为每年 56,000 美元，患者和医疗保险也可能面临检测费用。</blockquote></p><p> About six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.</p><p><blockquote>约有 600 万美国人患有阿尔茨海默氏症，这是一种会剥夺人们记忆和认知能力的进行性疾病。百健表示，其中多达200万人可能会从这种药物中受益。</blockquote></p><p> The FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.</p><p><blockquote>美国食品和药物管理局的批准使百健的股价飙升。该公司表示，预计今年该药物的收入将微乎其微，部分原因是管理该药物的后勤挑战，但销售额将在明年开始增长。</blockquote></p><p> Analysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.</p><p><blockquote>根据 FactSet 的数据，分析师预计 2022 年销售额为 9.463 亿美元。预计 2026 年销售额将增长至 52 亿美元。</blockquote></p><p> The memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.</p><p><blockquote>备忘录显示，美国食品和药物管理局官员正试图在 Aduhelm 的研究数据与阿尔茨海默氏症患者及其家人尝试任何可能有帮助的新疗法的愿望之间取得平衡。</blockquote></p><p></p><p> “There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.</p><p><blockquote>“斯坦因博士写道：”临床获益仍存在不确定性。但他写道，如果美国食品和药物管理局等待该公司完成另一项临床研究，“任何批准都将在多年的延迟之后进行”，患者 “可能会遭受不可逆转的大脑神经元、认知功能和记忆力丧失”。</blockquote></p><p> The FDA said it plans to release more documents regarding its decision making as early as next week.</p><p><blockquote>FDA表示，计划最早下周发布更多有关其决策的文件。</blockquote></p><p> The FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.</p><p><blockquote>美国食品和药物管理局的批准主要基于百健公司启动的两项大型 3 期临床试验，以证明其药物有助于减缓早期阿尔茨海默氏症患者的认知能力下降。</blockquote></p><p> In March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.</p><p><blockquote>2019 年 3 月，在独立监测委员会得出结论该药物不太可能帮助患者后，该公司提前停止了研究。</blockquote></p><p> Seven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.</p><p><blockquote>然而，七个月后，该公司做出了令人惊讶的逆转，并表示在对研究停止后获得的试验数据进行额外分析后，现在正计划寻求 FDA 的批准。该公司表示，其分析发现该药物在一项研究中取得了成功，但在第二项研究中失败。</blockquote></p><p> The FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.</p><p><blockquote>美国食品和药物管理局的备忘录提供了一些关于百健转变的新细节。根据一份 “摘要备忘录 ”文件，2019 年 6 月，该公司会见了 FDA 官员，双方一致认为不应停止研究。</blockquote></p><p> At the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.</p><p><blockquote>在会议上，FDA 官员建议百健进一步分析这些研究，以了解尽管试验停止且结果相互矛盾，但是否仍然有可能从数据中得出结论。</blockquote></p><p> Several months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.</p><p><blockquote>根据备忘录，几个月后，即 2019 年 10 月，该机构和公司再次会面，并一致认为这些研究仍可用于评估药物的有效性。</blockquote></p><p> The following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.</p><p><blockquote>第二天，即 10 月 22 日，百健宣布将寻求该药物的批准，从而推高其股价，并为其市值增加数十亿美元。</blockquote></p><p> The company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.</p><p><blockquote>百健公司首席执行官米歇尔-沃纳索斯（Michel Vounatsos）当时在接受采访时说，几个月来，公司一直在悄悄地重新审查这些数据，但直到最近一次与美国食品及药物管理局官员会面，公司才有信心继续前进。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2\">WSJ</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BIIB":"渤健公司"},"source_url":"https://www.wsj.com/articles/fda-approved-biogen-alzheimers-drug-despite-some-staff-concerns-11624393800?mod=hp_lead_pos2","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1174011543","content_text":"The U.S. Food and Drug Administrationapproved the first new Alzheimer’s drug in decadesover the objection of agency statisticians who said there was insufficient evidence to support approval, according to newly released internal memos.\nIn the internal memos released Tuesday, FDA officials discussed whether to approve the drug fromBiogenInc.BIIB-1.71%over objections from the agency’s drug statistics office, which said that clinical trial data fell short of the proof typically required to put a new product on the market.\nUltimately, top officials decided that the evidence indicating that the drug worked, while inconclusive, was strong enough to allow doctors and patients to decide for themselves whether to take it, according to the memos.\n“FDA, then, is faced with a situation where the available evidence on the clinical endpoints is short of what we would require for standard approval of aducanumab,” wrote Peter Stein, director of the FDA’s office of new drugs, in a memo detailing his support for approval. “At the same time, patients with [Alzheimer’s] have a serious, progressive, ultimately fatal disease and are desperate for treatments.”\nThe FDA made public its internal deliberations as it faces criticism from some doctors and scientists over the June 7 approval of the drug, called Aduhelm.\nThe critics say the FDA ignored the scientific standards it typically holds drugmakers to and could prompt the federal government to spend billions of dollars on a drug that may not work.\n“While I fully support the Center’s recent decision to approve the therapy, I acknowledge that there are different opinions about this decision, including within FDA, and there likely will continue to be questions around our process for review and the data we considered to support the approval,” said FDA Acting Commissioner Janet Woodcock. “In the end, an experienced group of medical reviewers at FDA concluded that there was sufficient evidence to approve the Alzheimer’s therapy via the accelerated approval pathway.”\nSupporters say the FDA decision provides a lifeline to patients who have lacked any medicine promising to slow the progression of Alzheimer’s, and that the decision couldspur the development of more, better medicines.\nThe agency usually releases approval documents after a decision, though not typically as quickly as it did this time. The 83 pages of memos appear to be a portion of the FDA’s deliberations, largely reflecting the exchanges of top officials.\nTristan Massie, a biostatistics reviewer for the FDA, “does not agree that the totality of the data provides sufficient evidence to support the efficacy of aducanumab in Alzheimer’s disease and does not recommend approval,” one of the internal documents shows.\nPatrizia Cavazzoni, the FDA’s top-ranking drug-evaluation official, wrote in another memo that the agency’s drug biostatistics office “provided documentation for its recommendation that substantial evidence of effectiveness had not been provided in the application.”\nThat office’s full dissenting analysis wasn’t included in the materials made available Tuesday, but portions of it were.\nDespite the objections, Dr. Cavazzoni wrote that Biogen had met the requirements for an “accelerated approval,” a type of regulatory clearance that allows a drug to be marketed even when there remains uncertainty about its clinical benefit if it fills an unmet need for a serious disease and has effects against a biological sign of the disease.\nDr. Cavazzoni wrote that Aduhelm met that standard because of its effect of reducing a sticky substance called amyloid which “is reasonably likely to predict clinical benefit.”\nSome doctors and scientists saytargeting the amyloid plaqueshasn’t been proven to slow Alzheimer’s. Some members of a panel of advisers that recommended the FDA reject the drug haveresigned from the committee, citing the agency’s approval.\nBiogen listed the price of Aduhelm at $56,000 a year, and patients and Medicare could also face testing charges.\nAbout six million Americans suffer from Alzheimer’s, a progressive condition that robs people of their memories and cognitive abilities. Biogen has said that as many as two million of them may benefit from the medicine.\nThe FDA approval sent Biogen’s stock soaring. The company has said it expects only minimal revenue from the drug this year, in part because of the logistical challenges in administering the medicine, but that sales would begin to increase next year.\nAnalysts estimate sales of $946.3 million in 2022, according to FactSet. Sales are seen growing to $5.2 billion in 2026.\nThe memos show FDA officials attempting to balance the subpar study data for Aduhelm with the desire of Alzheimer’s patients and their families to try any new treatment that might help.\n“There remains residual uncertainty regarding clinical benefit,” Dr. Stein wrote. But if the FDA were to wait for the company to finish another clinical study, “any approval would occur after a multiple year delay” and patients “could suffer irreversible loss of brain neurons and cognitive function and memory,” he wrote.\nThe FDA said it plans to release more documents regarding its decision making as early as next week.\nThe FDA’s approval was based primarily on two large Phase 3 clinical trials launched by Biogen to prove its drug helped slow the cognitive decline of people with early-stage Alzheimer’s.\nIn March 2019, the companyhalted the studies earlyafter an independent monitoring board concluded the drug was unlikely to help patients.\nSeven months later, however,the company made a surprising reversaland said it was now planning to seek FDA approval after conducting additional analyses of trial data that came in after the studies were halted. The company said its analyses found the drug was successful in one study but failed in the second.\nThe FDA memos provide some new details on Biogen’s about-face. In June 2019, the company met with FDA officials and both sides agreed the studies shouldn’t have been stopped, according to a “summary memorandum” document.\nAt the meeting, FDA officials recommended that Biogen analyze the studies further to understand if it was still possible to draw conclusions from the data, despite the halt of the trials and conflicting results.\nSeveral months later, in October 2019, the agency and company met again and agreed that the studies could still be used to evaluate the drug’s effectiveness, according to the memo.\nThe following day, on Oct. 22, Biogen announcedit would seek approval for the medicine, sending up its share price and adding billions of dollars to its market value.\nThe company had been quietly re-examining the data for months, but didn’t have the confidence to move forward until the latest meeting with FDA officials, Biogen Chief Executive Michel Vounatsos said in an interview at the time.","news_type":1,"symbols_score_info":{"BIIB":0.9}},"isVote":1,"tweetType":1,"viewCount":3669,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}